Selank Research Peptides

Selank is a synthetic seven-amino-acid peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). [S1] [S2]

Tuftsin is the four-amino-acid peptide TKPR. Selank contains that complete sequence and adds Pro-Gly-Pro, giving TKPRPGP. They are related but are not the same molecule. [S1] [S4]

No. N-acetyl Selank has an acetyl group on the N-terminus and is a chemically distinct analogue with its own PubChem record. Parent-Selank clinical evidence should not automatically be transferred to it. [S1] [S3]

Suppliers use this name for a Selank analogue described as N-terminally acetylated and C-terminally amidated. No authoritative public substance record for that exact doubly modified identity was located in this search, so the precise chemistry should be verified from sequence and analytical documentation rather than the marketing name. [S3] [S20]

No high-certainty conclusion is justified from the available evidence. Small Russian clinical studies report benefit in diagnosed anxiety-related conditions, but the accessible reports have important design and reporting limitations and have not been independently replicated at large scale. [S6] [S7] [S8]

That has not been established. Some small studies compared Selank with medazepam or phenazepam and reported similar or favourable outcomes, but the accessible reports do not document a formal equivalence or non-inferiority design. [S6] [S7]

This has not been demonstrated by the human evidence located. The healthy-volunteer study found short-term resting-state brain-connectivity differences, not validated improvements in memory, attention or everyday performance. [S9]

No controlled human sleep study establishing a sleep benefit was located in this search. Sleep claims should therefore not be presented as established. [S6] [S7] [S8] [S9]

That has not been established by adequate long-term human evidence. Short clinical studies and mechanistic differences from benzodiazepines are not sufficient to prove absence of dependence, withdrawal or sedation. [S6] [S7] [S8] [S16]

A robust primary human pharmacokinetic half-life was not located. Available degradation and route-comparison studies identified in this search are preclinical. [S10] [S14]

Targeted searches of the MHRA public product-information route did not locate a UK-authorised Selank medicine as of 22 September 2026. MHRA separately provides regulated routes for certain unlicensed medicines, which is not the same as a product holding a UK marketing authorisation. [S17] [S18]

A 2022 peer-reviewed review of Russian peptide medicines lists Selank among registered peptide drugs in the Russian Federation and classifies it as an anxiolytic. The primary Russian regulatory register was not independently verified in this research session, so exact current formulation and authorised indications are not asserted here. [S15]

No. Selank is TKPRPGP and is structurally related to tuftsin. Semax is the different heptapeptide MEHFPGP and has a separate research history. [S1] [S5]